No Data
No Data
Express News | Mira Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
Tariffs Expected to Bring Pharmaceutical Price Bumps, Shortages -- Market Talk
Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development
Express News | Mira Pharmaceuticals Inc - Submits Ind Application to FDA for Ketamir-2
Express News | Mira Pharmaceuticals Inc: Submission of Investigational New Drug (Ind) Application by End of 2024